iBio Inc is a biotechnology business based in the US. iBio shares (IBIO) are listed on the NYSE MKT and all prices are listed in US Dollars. iBio employs 49 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $0.52 |
|---|---|
| 52-week range | $0.48 - $2.83 |
| 50-day moving average | $0.66 |
| 200-day moving average | $1.12 |
| Wall St. target price | $2.25 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.52 from 2022-01-14
| 1 week (2022-01-12) | 4.00% |
|---|---|
| 1 month (2021-12-17) | -21.00% |
| 3 months (2021-10-19) | -42.22% |
| 6 months (2021-07-19) | -63.12% |
| 1 year (2021-01-19) | -65.56% |
|---|---|
| 2 years (2020-01-17) | 121.37% |
| 3 years (2019-01-18) | 0.87 |
| 5 years (2017-01-18) | 33.33% |
| Revenue TTM | $2.2 million |
|---|---|
| Gross profit TTM | $909,000 |
| Return on assets TTM | -15.81% |
| Return on equity TTM | -27.27% |
| Profit margin | 0% |
| Book value | $0.46 |
| Market capitalisation | $112.2 million |
TTM: trailing 12 months
We're not expecting iBio to pay a dividend over the next 12 months.
iBio's shares were split on a 1:10 basis on 10 June 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iBio shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for iBio shares which in turn could have impacted iBio's share price.
Over the last 12 months, iBio's shares have ranged in value from as little as $0.481 up to $2.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while iBio's is -6.0172. This would suggest that iBio's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, iBio has bucked the trend.
iBio, Inc. , a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
